{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:47:32Z","timestamp":1768816052656,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T00:00:00Z","timestamp":1251244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00296-009-1111-4","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T06:14:02Z","timestamp":1251180842000},"page":"1063-1070","source":"Crossref","is-referenced-by-count":34,"title":["A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis"],"prefix":"10.1007","volume":"30","author":[{"given":"Astrid","family":"Wiens","sequence":"first","affiliation":[]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,8,26]]},"reference":[{"key":"1111_CR1","first-page":"151","volume":"47","author":"M B\u00e9rtolo","year":"2007","unstructured":"B\u00e9rtolo M, Brenol C, Schainberg C, Neubarth F (2007) Atualiza\u00e7\u00e3o do consenso brasileiro no diagn\u00f3stico e tratamento da artrite reumat\u00f3ide. Rev Bras Reumatol 47:151\u2013159","journal-title":"Rev Bras Reumatol"},{"key":"1111_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429\u2013442","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"1111_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.rheumatology.a031494","volume":"39","author":"P Tugwell","year":"2000","unstructured":"Tugwell P (2000) Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl 1):43\u201347","journal-title":"Rheumatology (Oxford)"},{"key":"1111_CR4","volume-title":"Reumatologia\u2014Princ\u00edpios e pr\u00e1tica","author":"TL Skare","year":"1999","unstructured":"Skare TL (1999) Reumatologia\u2014Princ\u00edpios e pr\u00e1tica. Guanabara e Koogan Ltda, Rio de Janeiro"},{"key":"1111_CR5","first-page":"1710","volume":"33","author":"S Yurdakul","year":"2006","unstructured":"Yurdakul S (2006) Prevalence of rheumatoid arthritis. J Rheumatol 33:1710 (author reply 1710)","journal-title":"J Rheumatol"},{"key":"1111_CR6","doi-asserted-by":"crossref","unstructured":"Brenol C, Monticielo O, Xavier R, Brenol J (2007) Artrite reumat\u00f3ide e aterosclerose. Revista da associa\u00e7\u00e3o m\u00e9dica brasileira, p 53","DOI":"10.1590\/S0104-42302007000500026"},{"key":"1111_CR7","unstructured":"Sato EI, Ciconelli RM (2000) Artrite reumat\u00f3ide. Revista brasileira de medicina, p 57"},{"key":"1111_CR8","unstructured":"Secretaria da Ci\u00eancia (2006) Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas - Artrite Reumat\u00f3ide, p 21"},{"key":"1111_CR9","first-page":"1179","volume":"65","author":"Y Tanaka","year":"2007","unstructured":"Tanaka Y (2007) Biologics: current therapeutic strategies for rheumatoid arthritis. Nippon Rinsho 65:1179\u20131184","journal-title":"Nippon Rinsho"},{"key":"1111_CR10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/kem074","volume":"46","author":"CA Walsh","year":"2007","unstructured":"Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale BJ et al (2007) Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 46:1148\u20131152","journal-title":"Rheumatology"},{"key":"1111_CR11","first-page":"554","volume":"60","author":"RG Silva","year":"2003","unstructured":"Silva RG, Vannucci AB, Latorre LC, Zerbini CAF (2003) Artrite reumat\u00f3ide. Revista brasileira de medicina 60:554\u2013577","journal-title":"Revista brasileira de medicina"},{"key":"1111_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","volume":"126","author":"M Wong","year":"2008","unstructured":"Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J et al (2008) TNF-alpha blockade in human diseases: mechanisms and future directions. Clin Immunol 126:121\u2013136","journal-title":"Clin Immunol"},{"key":"1111_CR13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","volume":"62","author":"LB Putte van de","year":"2003","unstructured":"van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL et al (2003) Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12\u00a0week, phase II study. Ann Rheum Dis 62:1168\u20131177","journal-title":"Ann Rheum Dis"},{"key":"1111_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"1111_CR15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"1111_CR16","unstructured":"Review Manager (RevMan) [Computer program] (2008) Version 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen"},{"key":"1111_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.2004.034769","volume":"65","author":"A Hakkinen","year":"2006","unstructured":"Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Makinen H, Sokka T (2006) Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 65:30\u201334","journal-title":"Ann Rheum Dis"},{"key":"1111_CR18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11:193\u2013206","journal-title":"Psychol Methods"},{"key":"1111_CR19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","volume":"18","author":"N Miyasaka","year":"2008","unstructured":"Miyasaka N (2008) Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 18:252\u2013262","journal-title":"Mod Rheumatol"},{"key":"1111_CR20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB Putte van de","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508\u2013516","journal-title":"Ann Rheum Dis"},{"key":"1111_CR21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"1111_CR22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"1111_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1479-8077.2007.00248.x","volume":"10","author":"HY Kim","year":"2007","unstructured":"Kim HY, Lee SK, Song YW, Koh EM, Yoo B, Luo A (2007) A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with metotrexate. APLAR J Rheumatol 10:9\u201316","journal-title":"APLAR J Rheumatol"},{"key":"1111_CR24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"},{"key":"1111_CR25","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleishmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of Adalimumab in rheumatoid arthritis). J Rheumatol 30:2563\u20132571","journal-title":"J Rheumatol"},{"key":"1111_CR26","first-page":"6","volume":"125","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 125:6\u20131278","journal-title":"Lancet"},{"key":"1111_CR27","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1517\/14656566.8.13.2089","volume":"8","author":"E Toussirot","year":"2007","unstructured":"Toussirot E, Wendling D (2007) The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 8:2089\u20132107","journal-title":"Expert Opin Pharmacother"},{"key":"1111_CR28","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0149-2918(08)80063-X","volume":"30","author":"T Boxiong","year":"2008","unstructured":"Boxiong T, Rahman M, Waters HC, Callegari P (2008) Treatment persistence with Adalimumab, Etanercept, or Infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30:1375\u20131384","journal-title":"Clin Ther"},{"key":"1111_CR29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"1111_CR30","first-page":"1075","volume":"33","author":"F Navarro-Sarabia","year":"2006","unstructured":"Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (2006) Adalimumab for treating rheumatoid arthritis. J Rheumatol 33:1075\u20131081","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-1111-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1111-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:18:34Z","timestamp":1559042314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-1111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,26]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-1111-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,26]]}}}